Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Margaret MacRury steps down as Rowlands superintendent after a decade of service

Margaret MacRury has stepped down from her role as superintendent director for the Rowlands Pharmacy, which has a community pharmacy network in England, Scotland and Wales with more than 450 branches.

MacRury, who served the role for a decade, will step down next month to focus on the pharmacy contract developments taking place in Scotland, Rowlands said in a statement.


She will start her new role in February 2022.

With MacRury leaving the position, Stephen Thomas, currently her deputy, will take up the role of superintendent for Rowlands. He has been with the multiple for nearly 18 years and has worked side-by-side with MacRury for the last decade.

MacRury stated: “I know Stephen will continue that commitment to protecting patients and promoting the pharmacy sector.

“During my time as superintendent director I have seen our sector ever increasingly being recognized as a critical part of the NHS “family” providing essential access to much-needed healthcare support and advice alongside dispensing. These are exciting times which Stephen will take forward.

“I believe that the Scottish government understands the unique value of community pharmacy in delivering improved healthcare outcomes. Going forward, I will continue to play my part, alongside Stephen, in promoting community pharmacy not just in Scotland, but throughout Great Britain.”

Stephen Thomas Stephen Thomas

On acquiring new role, Thomas stated: “Our sector faces many challenges, but also new opportunities. Community pharmacy is the third pillar of our national healthcare service alongside GP surgeries and hospitals. With fair and sustainable funding it can, and does, transform lives.

“PHOENIX will continue to pioneer innovative healthcare provision such as bricks & clicks, blending physical and digital services, whilst at all times putting the patient at the heart of what we do.”

Rowland is a division of PHOENIX Group, which is one of Europe’s largest and integrated pharmaceutical providers, offering wholesale, retail and pharma services.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less